| Abatacept for treating active idiopathic inflammatory myopathies [TSID10095] | Technology appraisal guidance |
| Acalabrutinib for treating relapsed or refractory mantle cell lymphoma [ID6389] | Technology appraisal guidance |
| Acalabrutinib with R-CHOP for untreated non-germinal centre B-cell diffuse large B-cell lymphoma [ID6614] | Technology appraisal guidance |
| Acalabrutinib with venetoclax and obinutuzumab for untreated chronic lymphocytic leukaemia [ID6156] | Technology appraisal guidance |
| Adalimumab for treating early Dupuytren's contracture [ID6276] | Technology appraisal guidance |
| Afamitresgene autoleucel for previously treated MAGE-A4 positive advanced synovial sarcoma or myxoid round cell liposarcoma [ID4064] | Technology appraisal guidance |
| Aficamten for treating symptomatic obstructive hypertrophic cardiomyopathy [ID6575] | Technology appraisal guidance |
| Alpelisib for treating severe PIK3CA-related overgrowth spectrum in people 2 years and over [ID6252] | Technology appraisal guidance |
| Alpha-1 antitrypsin for treating high-risk acute graft-versus-host disease after a haematopoietic stem cell transplant in people 12 years and over [TSID12036] | Technology appraisal guidance |
| Apadamtase alfa for preventing and treating congenital thrombotic thrombocytopenic purpura caused by ADAMTS-13 deficiency [ID6192] | Technology appraisal guidance |
| Apalutamide with radical prostatectomy for untreated high-risk, localised or locally advanced prostate cancer [ID6471] | Technology appraisal guidance |
| Aprocitentan for treating resistant hypertension [TSID10395] | Technology appraisal guidance |
| Atezolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID3894] | Technology appraisal guidance |
| Atezolizumab for adjuvant treatment of circulating tumour DNA-positive high-risk muscle-invasive bladder cancer after cystectomy [ID6515] | Technology appraisal guidance |
| Atogepant for treating migraine [ID6615] | Technology appraisal guidance |
| Atrasentan for treating primary IgA nephropathy [ID6558] | Technology appraisal guidance |
| Avexitide for treating hypoglycaemia after bariatric surgery [TSID12233] | Technology appraisal guidance |
| Axatilimab for treating active chronic graft-versus-host disease after 2 or more systemic treatments in people 2 years and over [ID6570] | Technology appraisal guidance |
| Baloxavir marboxil for Influenza [ID6552] | Technology appraisal guidance |
| Baloxavir marboxil for influenza prophylaxis in people aged 12 and over [ID3793] | Technology appraisal guidance |
| Baloxavir marboxil for treating influenza in babies under 1 year [ID6555] | Technology appraisal guidance |
| Baloxavir marboxil for treating influenza in people at high risk of complications [ID3794] | Technology appraisal guidance |
| Baricitinib for treating severe or very severe alopecia areata in people 6 to 17 years [ID6541] | Technology appraisal guidance |
| Baxdrostat for treating uncontrolled or resistant hypertension [ID6623] | Technology appraisal guidance |
| Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 2 therapies [ID5108] | Technology appraisal guidance |
| Belzutifan with pembrolizumab and lenvatinib for untreated advanced clear cell renal cell carcinoma [ID6605] | Technology appraisal guidance |
| Belzutifan with pembrolizumab for adjuvant treatment of clear cell renal cell carcinoma after nephrectomy [TSID12229] | Technology appraisal guidance |
| Benegrastim for treating chemotherapy-induced neutropenia in people with breast cancer [TSID11769] | Technology appraisal guidance |
| Benralizumab for treating hypereosinophilic syndrome in people 12 years and over [ID6322] | Technology appraisal guidance |
| Benralizumab to reduce exacerbations in moderate to very severe chronic obstructive pulmonary disease [ID1394] | Technology appraisal guidance |
| Bentracimab for reversing the antiplatelet activity of ticagrelor [TSID10550][ID6344] | Technology appraisal guidance |
| Bevacizumab (Avastin and biosimilars) with fluoropyrimidine-based chemotherapy for untreated metastatic colorectal cancer [ID6465] | Technology appraisal guidance |
| Bifikafusp alfa–onfekafusp alfa for neoadjuvant treatment of 3B or 3C resectable melanoma [ID6384] | Technology appraisal guidance |
| Bimekizumab for treating ankylosing spondylitis [ID4011] | Technology appraisal guidance |
| Blarcamesine for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [TSID12157] | Technology appraisal guidance |
| Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive B-precursor acute lymphoblastic leukaemia with no measurable residual disease [ID6405] | Technology appraisal guidance |
| Botaretigene sparoparvovec for treating RPGR mutation-associated X-linked retinitis pigmentosa [ID6286] | Technology appraisal guidance |
| Botulinum toxin type A for preventing episodic migraine [ID6450] | Technology appraisal guidance |
| Brentuximab vedotin with etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone for untreated advanced classical Hodgkin lymphoma [ID6437] | Technology appraisal guidance |
| Budesonide (Jorveza) for maintaining remission of eosinophilic oesophagitis in people 2 years and over [ID6486] | Technology appraisal guidance |
| Bupivacaine–meloxicam for treating postoperative pain [ID2728] | Technology appraisal guidance |
| Cabotegravir with rilpivirine for the oral treatment of HIV-1 [ID3731] | Technology appraisal guidance |
| Cabozantinib with atezolizumab for treating hormone-relapsed metastatic prostate cancer after 1 hormonal treatment [ID6387] | Technology appraisal guidance |
| CAEL-101 with standard care for untreated amyloid light chain amyloidosis [ID6210] | Technology appraisal guidance |
| Camizestrant as an add-on to palbociclib and abemaciclib for untreated hormone receptor-positive HER2-negative metastatic breast cancer with an ESR1 mutation
[ID6535] | Technology appraisal guidance |
| Camizestrant with palbociclib for untreated oestrogen receptor-positive HER2-negative metastatic breast cancer after adjuvant endocrine treatment [ID6534] | Technology appraisal guidance |
| Camlipixant for treating refractory or unexplained chronic cough [TSID12072] | Technology appraisal guidance |
| Canagliflozin for treating type 2 diabetes in people 10 to 17 years [TSID11888] | Technology appraisal guidance |
| Carfilzomib in combination for untreated multiple myeloma when an autologous stem cell transplant is suitable [TSID12176] | Technology appraisal guidance |
| Cenobamate for adjunctive treatment of primary generalised tonic-clonic seizures in epilepsy [TSID10214] | Technology appraisal guidance |
| Ceralasertib with durvalumab for treating advanced non-small-cell lung cancer after antiPD-L1 treatment and platinum-based chemotherapy [ID6612] | Technology appraisal guidance |
| Clascoterone for treating acne vulgaris in people 12 years and over [ID6572] | Technology appraisal guidance |
| Cobolimab with dostarlimab and docetaxel for treating advanced non-small-cell lung cancer after anti-PD-L1 treatment and chemotherapy [ID6398] | Technology appraisal guidance |
| Concizumab for preventing bleeding episodes in haemophilia A or haemophilia B [ID5099] | Technology appraisal guidance |
| Dabigatran etexilate for the secondary prevention of stroke after an embolic stroke of undetermined source [ID1417] | Technology appraisal guidance |
| Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma in people aged 12 to 17 [TSID11839] | Technology appraisal guidance |
| Dabrafenib, trametinib or both for treating BRAF V600 mutation-positive unresectable or metastatic melanoma in people aged 12 and over [TSID11838] | Technology appraisal guidance |
| Daratumumab for treating high-risk smouldering multiple myeloma [ID6214] | Technology appraisal guidance |
| Datopotamab deruxtecan for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer [ID6435] | Technology appraisal guidance |
| Datopotamab deruxtecan with durvalumab and carboplatin for untreated TROP2-positive advanced non-small-cell lung cancer without actionable genomic alterations [ID6522] | Technology appraisal guidance |
| Datopotamab deruxtecan with durvalumab for treating triple-negative breast cancer when there is residual invasive disease after neoadjuvant systemic treatment and surgery [TSID12242] | Technology appraisal guidance |
| Decitabine–cedazuridine with venetoclax for treating acute myeloid leukaemia when induction chemotherapy is unsuitable [ID6601] | Technology appraisal guidance |
| Delgocitinib for Chronic Hand Eczema [ID12188] | Technology appraisal guidance |
| Denosumab biosimilar for Giant cell-rich tumours of bone or Skeletal events in bone malignancies ID12150 | Technology appraisal guidance |
| Deucravacitinib for treating active psoriatic arthritis [TSID11981] | Technology appraisal guidance |
| Dexamethasone intracanalicular insert for treating inflammation and pain after cataract surgery [ID1154] | Technology appraisal guidance |
| Domvanalimab with zimberelimab for untreated unresectable advanced gastric, gastro-oesophageal junction or oesophageal cancer [ID6606] | Technology appraisal guidance |
| Dorocubicel for treating haematological cancer when a suitable donor is unavailable for an allogeneic haematopoietic stem cell transplant [ID6521] | Technology appraisal guidance |
| Doxecitine–doxribtimine for treating thymidine kinase 2 deficiency in people of any age who had symptoms before 13 years [TSID12046] | Technology appraisal guidance |
| Dulaglutide for treating type 2 diabetes [ID1451] | Technology appraisal guidance |
| Dupilumab for treating bullous pemphigoid [ID6479] | Technology appraisal guidance |
| Dupilumab for treating eosinophilic oesophagitis in children 1 to 11 years [ID6492] | Technology appraisal guidance |
| Durvalumab (Imfinzi) +/- bevacizumab (Avastin) for hepatocellular carcinoma [TSID10736] | Technology appraisal guidance |
| Durvalumab for adjuvant treatment of hepatocellular carcinoma at high risk of recurrence after curative liver resection or ablation [ID6206] | Technology appraisal guidance |
| Durvalumab in combination for untreated advanced ovarian, fallopian tube or primary peritoneal cancer before and after surgery [ID6254] | Technology appraisal guidance |
| Durvalumab with BCG for treating high-risk non-muscle-invasive bladder cancer after resection of papillary tumours in people previously untreated with BCG [ID5080] | Technology appraisal guidance |
| Durvalumab with bevacizumab and transarterial chemoembolisation for treating locally advanced hepatocellular carcinoma [ID3944] | Technology appraisal guidance |
| Durvalumab with bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence [ID6146] | Technology appraisal guidance |
| Durvalumab with enfortumab vedotin for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer when cisplatin is unsuitable [ID6445] | Technology appraisal guidance |
| Durvalumab with oleclumab or monalizumab for treating unresectable locally advanced non-small-cell lung cancer after platinum-based chemoradiotherapy [ID6626] | Technology appraisal guidance |
| Durvalumab with or without bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence [ID6428] | Technology appraisal guidance |
| Durvalumab with radiotherapy for treating unresected node-negative stage 1 or 2 non-small-cell lung cancer [ID6567] | Technology appraisal guidance |
| Durvalumab with transarterial chemoembolisation for treating incurable locally advanced hepatocellular carcinoma [ID5124] | Technology appraisal guidance |
| Durvalumab with tremelimumab and transarterial chemoembolisation with or without lenvatinib for treating locally advanced hepatocellular carcinoma PD [ID6527] | Technology appraisal guidance |
| Durvalumab with tremelimumab for treating limited-stage small-cell lung cancer after chemoradiation [ID5097] | Technology appraisal guidance |
| Dusquetide for treating oral mucositis during chemoradiation for head and neck cancer [ID3830] | Technology appraisal guidance |
| Duvelisib for treating relapsed or refractory peripheral T-cell lymphoma [ID5076] | Technology appraisal guidance |
| Edaravone for treating amyotrophic lateral sclerosis [TSID11869] | Technology appraisal guidance |
| Eflornithine with lomustine for treating anaplastic astrocytoma after radiotherapy and adjuvant temozolomide [TSID10046] | Technology appraisal guidance |
| Efzimfotase alfa for treating hypophosphatasia in people 2 years and over [TSID12257] | Technology appraisal guidance |
| Elamipretide for treating Barth syndrome in people of any age [ID6545] | Technology appraisal guidance |
| Elinzanetant for treating vasomotor symptoms associated with menopause [ID6359] | Technology appraisal guidance |
| Elinzanetant for treating vasomotor symptoms caused by adjuvant endocrine treatment to prevent or treat hormone-receptor positive breast cancer [ID6544] | Technology appraisal guidance |
| Elinzanetant for Vasomotor symptoms [ID6544] | Technology appraisal guidance |
| Elranatamab for treating relapsed or refractory multiple myeloma after 2 treatments [ID6464] | Technology appraisal guidance |
| Elranatamab for treating relapsed or refractory multiple myeloma after treatments including anti-CD38 antibody and lenalidomide therapy [ID6591] | Technology appraisal guidance |
| Eneboparatide for treating chronic hypoparathyroidism [ID6532] | Technology appraisal guidance |
| Eneboparatide for treating chronic hypoparathyroidism [TSID12145] | Technology appraisal guidance |
| Enfortumab vedotin with pembrolizumab for neoadjuvant and adjuvant treatment of cisplatin-eligible muscle-invasive bladder cancer [ID6301] | Technology appraisal guidance |
| Enfortumab vedotin with pembrolizumab for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer when cisplatin is unsuitable [ID6607] | Technology appraisal guidance |
| Ensitrelvir for treating COVID 19 [ID6231] | Technology appraisal guidance |
| Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after first-line systemic treatment [ID6463] | Technology appraisal guidance |
| Eplontersen for treating transthyretin-related amyloidosis cardiomyopathy [TSID12015] | Technology appraisal guidance |
| Estetrol for treating vasomotor symptoms associated with the menopause in people aged 40 to 65 [ID4037] | Technology appraisal guidance |
| Etripamil for treating paroxysmal supraventricular tachycardia [ID6581] | Technology appraisal guidance |
| Etrolizumab for treating moderately to severely active ulcerative colitis [ID3827] | Technology appraisal guidance |
| Favezelimab–pembrolizumab for previously treated PD-L1-positive metastatic colorectal cancer [ID6278] | Technology appraisal guidance |
| Fenebrutinib for treating primary progressive multiple sclerosis [ID6543] | Technology appraisal guidance |
| Fenebrutinib for treating relapsing multiple sclerosis [ID6577] | Technology appraisal guidance |
| Fidrisertib for reducing heterotopic ossification caused by fibrodysplasia ossificans progressiva in people 5 years and over
[TSID12216] | Technology appraisal guidance |
| Filgotinib for Axial spondyloarthritis [ID6594] | Technology appraisal guidance |
| Fostemsavir for treating adults with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2726] | Technology appraisal guidance |
| Galcanezumab for migraine [TSID10663] | Technology appraisal guidance |
| Gantenerumab for treating early Alzheimer's disease [TSID10668] | Technology appraisal guidance |
| Gefurulimab for treating antibody-positive generalised myasthenia gravis [TSID12256] | Technology appraisal guidance |
| Giredestrant with everolimus for treating oestrogen-receptor positive HER2-negative advanced breast cancer after CDK 4/6 inhibitor and endocrine treatment [ID6576] | Technology appraisal guidance |
| Giredestrant with palbociclib for untreated oestrogen-receptor positive HER2-negative advanced breast cancer [ID5072] | Technology appraisal guidance |
| Golimumab biosimilar for Rheumatoid Arthritis, Juvenile Arthritis, Ankylosing Spondylitis, Axial Spondyloarthropathy, Psoriatic Arthritis, and Ulcerative Colitis [ID12208] | Technology appraisal guidance |
| Gosuranemab for treating progressive supranuclear palsy [ID1607] | Technology appraisal guidance |
| Hepatocellular carcinoma (unresectable, untreated) - tislelizumab [ID6129] | Technology appraisal guidance |
| Human acellular vessel (Humacyl; HAV) For use as an arterial venous access for patients with end stage renal disease (ESRD) requiring haemodialysis [ID3747] | Technology appraisal guidance |
| Ianalumab for treating active Sjogren's syndrome [TSID12247] | Technology appraisal guidance |
| Ibalizumab for treating adults infected with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2720] | Technology appraisal guidance |
| Icotrokinra for treating moderate to severe plaque psoriasis in people 12 years and over [ID6579] | Technology appraisal guidance |
| Imetelstat for treating intermediate-2 or high-risk relapsed or refractory myelofibrosis after a JAK inhibitor [TSID8376] | Technology appraisal guidance |
| Inclacumab for preventing recurrent vaso-occlusive crises in sickle cell disease in people 16 years and over
[ID6551] | Technology appraisal guidance |
| Inclisiran for treating familial hypercholesterolaemia and elevated low density lipoprotein cholesterol in people 12 to 17 years [TSID12129] | Technology appraisal guidance |
| Inebilizumab for treating generalised myasthenia gravis [ID6587]
[TSID12110] | Technology appraisal guidance |
| Inebilizumab for treating immunoglobulin G4-related disease
[TSID12107] | Technology appraisal guidance |
| Inolimomab (Leukotac) for acute Graft versus host disease (aGvHD) after Allo-HSCT [ID3923] | Technology appraisal guidance |
| Invimestrocel for treating acute ischaemic stroke within 18 to 36 hours of onset [TSID10190] | Technology appraisal guidance |
| Iptacopan for treating primary IgA nephropathy
[TSID12248] | Technology appraisal guidance |
| Irbesartan–propagermanium for treating focal segmental glomerulosclerosis in people 12 years and over having an angiotensin II receptor blocker [ID6469] | Technology appraisal guidance |
| Isatuximab in combination as induction therapy for untreated multiple myeloma when an autologous stem cell transplant is suitable [TSID11949] | Technology appraisal guidance |
| Isatuximab in combination for maintenance treatment of newly diagnosed multiple myeloma after an autologous stem cell transplant
[TSID12243] | Technology appraisal guidance |
| Istradefylline with levodopa for treating motor fluctuations in Parkinson's disease [ID3868] | Technology appraisal guidance |
| Ixekizumab for treating enthesitis-related arthritis and juvenile psoriatic arthritis in people 2 to 17 years [ID6590] | Technology appraisal guidance |
| LAM-561 with radiotherapy and temozolomide for treating IDH1 wild-type glioblastoma [ID4022] | Technology appraisal guidance |
| Larotrectinib for treating NTRK fusion-positive advanced solid tumours (MA review of TA630) [ID6292] | Technology appraisal guidance |
| Leriglitazone for treating X-linked andrenoleukodystrophy [TSID9996] | Technology appraisal guidance |
| Letetresgene autoleucel for treating NY-ESO-1 advanced unresectable synovial sarcoma in people aged 10 and over or NY-ESO-1 advanced unresectable myxoid round cell liposarcoma in adults [TSID10652] | Technology appraisal guidance |
| Linerixibat for treating pruritus in people with primary biliary cholangitis [ID6265] | Technology appraisal guidance |
| Liposomal cytarabine–daunorubicin for treating relapsed or refractory acute myeloid leukaemia in people aged 1 to 21 years [ID4017] | Technology appraisal guidance |
| Lisocabtagene maraleucel for treating relapsed or refractory low-grade B-cell follicular lymphoma after 1 or more treatments [ID6564] | Technology appraisal guidance |
| Luspatercept for treating anaemia in non-transfusion dependent beta-thalassaemia [ID3870] | Technology appraisal guidance |
| Marstacimab for treating severe haemophilia A or B in people 12 years and over with inhibitors to factor-replacement therapy
[TSID12143] | Technology appraisal guidance |
| Mavorixafor for treating WHIM syndrome [ID3946] | Technology appraisal guidance |
| Mevrometostat with enzalutamide for treating hormone-relapsed metastatic prostate cancer after abiraterone acetate
[TSID12239] | Technology appraisal guidance |
| Mezigdomide with dexamethasone and carfilzomib for treating relapsed or refractory multiple myeloma after at least 1 line of treatment [ID6513] | Technology appraisal guidance |
| MIM8 for preventing bleeding episodes in haemophilia A in people 1 year and over [ID6400] | Technology appraisal guidance |
| Mirabegron for treating neurogenic detrusor overactivity in people aged 3 to 17 [TSID10730] | Technology appraisal guidance |
| Mirdametinib for treating symptomatic inoperable plexiform neurofibromas in people 2 years and over with neurofibromatosis type 1 [ID6618] | Technology appraisal guidance |
| Mozafancogene autotemcel for treating Fanconi anaemia in people 1 to 17 years [ID12203] | Technology appraisal guidance |
| Nedosiran treating primary hyperoxaluria type 1 in people 6 years and over [TSID11777] | Technology appraisal guidance |
| Netarsudil for treating open angle glaucoma or ocular hypertension [ID1078] | Technology appraisal guidance |
| Nicardipine (Nicaplant) for aneurysmal subarachnoid haemorrhage patients undergoing aneurysm clipping [TSID10593] | Technology appraisal guidance |
| Nipocalimab for treating generalised myasthenia gravis [ID6562] | Technology appraisal guidance |
| Niraparib with abiraterone acetate and prednisone for treating hormone-sensitive metastatic prostate cancer [ID6595] | Technology appraisal guidance |
| Nivolumab with ipilimumab for adjuvant treatment of localised renal cell carcinoma [TSID9659] | Technology appraisal guidance |
| Norucholic acid for treating primary sclerosing cholangitis [ID6583] | Technology appraisal guidance |
| Obicetrapib or obicetrapib–ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia [ID6519] | Technology appraisal guidance |
| Odevixibat for treating biliary atresia in children following Kasai hepatoportoenterostomy [ID6627] | Technology appraisal guidance |
| Odronextamab for treating relapsed or refractory follicular lymphoma [TSID12236] | Technology appraisal guidance |
| Omecamtiv mecarbil for treating chronic heart failure with reduced ejection fraction [ID3912] | Technology appraisal guidance |
| Onasemnogene abeparvovec for treating spinal muscular atrophy in people 2 years and over [TSID12168] | Technology appraisal guidance |
| Ondansetron for treating alcohol-use disorder [ID6341] | Technology appraisal guidance |
| Opicapone for adjunctive treatment of motor signs and symptoms in Parkinson's disease TS ID 11941 | Technology appraisal guidance |
| Ovarian, fallopian tube, peritoneal cancer (platinum sensitive) - rucaparib (with nivolumab, maintenance, after 1 therapy) [ID6128] | Technology appraisal guidance |
| Oveporexton for treating type 1 narcolepsy [ID6622] | Technology appraisal guidance |
| Palbociclib for treating high-risk early breast cancer after neoadjuvant chemotherapy [ID3846] | Technology appraisal guidance |
| Pariglasgene brecaparvovec for treating glycogen storage disease type 1a in people 8 years and over [TSID11865] | Technology appraisal guidance |
| Patritumab deruxtecan for treating EGFR mutation-positive advanced non-small-cell lung cancer after 1 or 2 tyrosine kinase inhibitor treatment [ID6467] | Technology appraisal guidance |
| Pegargiminase with pemetrexed and cisplatin for untreated advanced malignant pleural
mesothelioma [ID1575] | Technology appraisal guidance |
| Pelacarsen for reducing the risk of cardiovascular events in people with established cardiovascular disease and hyperlipidaemia [ID6559] | Technology appraisal guidance |
| Pembrolizumab adjuvant for urothelial carcinoma and/or localised muscle invasive bladder cancer [TSID12021] | Technology appraisal guidance |
| Pembrolizumab for adjuvant treatment of triple-negative breast cancer after neoadjuvant chemotherapy [ID6546] | Technology appraisal guidance |
| Pembrolizumab with BCG for treating high-risk non-muscle-invasive bladder cancer [ID6271] | Technology appraisal guidance |
| Pembrolizumab with chemoradiation for untreated high-risk advanced cervical cancer [TSID10690] | Technology appraisal guidance |
| Pembrolizumab with chemoradiation for untreated high-risk locally advanced cervical cancer [ID6138] | Technology appraisal guidance |
| Pembrolizumab with chemoradiation for untreated muscle-invasive non-metastatic bladder cancer [ID6613] | Technology appraisal guidance |
| Pembrolizumab with chemoradiotherapy for untreated unresectable oesophageal cancer [ID6270] | Technology appraisal guidance |
| Pembrolizumab with chemotherapy for adjuvant treatment of newly diagnosed high-risk endometrial cancer after surgery with curative intent [TSID11808] | Technology appraisal guidance |
| Pembrolizumab with chemotherapy for neoadjuvant and adjuvant treatment of cisplatin-eligible muscle-invasive bladder cancer [ID6219] | Technology appraisal guidance |
| Pembrolizumab with chemotherapy for treating hormone receptor-positive HER2-negative locally recurrent inoperable or metastatic breast cancer [ID6285] | Technology appraisal guidance |
| Pembrolizumab with enzalutamide and androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer [TSID11810] | Technology appraisal guidance |
| Pembrolizumab with neoadjuvant chemotherapy and adjuvant endocrine therapy for treating ER-positive, HER2-negative early breast cancer [ID3993] | Technology appraisal guidance |
| Perampanel for adjunctive treatment of partial onset or generalised tonic-clonic seizures in children aged below 12 years with epilepsy [ID1587] | Technology appraisal guidance |
| Pirtobrutinib for treating relapsed or refractory mantle cell lymphoma untreated with a BTK inhibitor [ID6493] | Technology appraisal guidance |
| Pirtobrutinib with venetoclax and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6566] | Technology appraisal guidance |
| Plinabulin with docetaxel for previously treated advanced non-small-cell lung cancer [ID3895] | Technology appraisal guidance |
| PLX-PAD for treating muscle injury after arthroplasty for hip fracture in people 60 to 90 years [ID3989] | Technology appraisal guidance |
| Port Delivery platform with ranibizumab for treating wet age-related macular degeneration [ID3983] | Technology appraisal guidance |
| Povorcitinib for treating moderate to severe active hidradenitis suppurativa after a TNF-alpha inhibitor [ID6569] | Technology appraisal guidance |
| Pridopidine for treating Huntington's disease [ID6525] | Technology appraisal guidance |
| Prostate cancer (hormone relapsed, homologous recombination deficiency, metastatic) – rucaparib (after 1 therapy) [ID6127] | Technology appraisal guidance |
| PXT3003 for treating Charcot-Marie-Tooth disease type 1A in people aged 16 and over [TSID9130] | Technology appraisal guidance |
| Ranibizumab port delivery system for treating diabetic macular oedema [ID6137] | Technology appraisal guidance |
| Ravulizumab for preventing kidney events in people with chronic kidney disease at high risk after a cardiopulmonary bypass [TSID12258] | Technology appraisal guidance |
| REGN5458 for treating relapsed or refractory multiple myeloma [ID6609] | Technology appraisal guidance |
| Remdesivir for treating COVID 19 [ID3808] | Technology appraisal guidance |
| Resmetirom for treating non-alcoholic steatohepatitis and liver fibrosis [TSID11905] [ID6529] | Technology appraisal guidance |
| Resminostat for maintenance treatment of advanced mycosis fungoides or Sezary syndrome [ID6478] | Technology appraisal guidance |
| Retatrutide for managing overweight and obesity
[TSID12259] | Technology appraisal guidance |
| Retifanlimab with chemotherapy for previously untreated metastatic non-small-cell lung cancer [ID6436] | Technology appraisal guidance |
| Retifanlimab with platinum-based chemotherapy for treating inoperable, locally recurrent or metastatic squamous cell anal canal cancer untreated with systemic chemotherapy
[ID6482] | Technology appraisal guidance |
| Ritlecitinib for treating non-segmental vitiligo in people 12 years and over [ID6584] | Technology appraisal guidance |
| Rivaroxaban for treating chronic heart failure [ID1462] | Technology appraisal guidance |
| Rivoceranib for treating unresectable or advanced gastric or gastro-oesophageal junction cancer after 2 or more therapies [ID3819] | Technology appraisal guidance |
| Rocatinlimab for treating moderate to severe atopic dermatitis in people 12 years and over [ID6565] | Technology appraisal guidance |
| Rucaparib for treating hormone-relapsed metastatic prostate cancer with homologous recombination deficiency after 1 therapy [TSID10764] | Technology appraisal guidance |
| Rucaparib with nivolumab for maintenance treatment of platinum-sensitive advanced ovarian, fallopian tube or peritoneal cancer after 1 therapy [TSID10763] | Technology appraisal guidance |
| Ruxolitinib for treating acute graft-versus-host disease after allogeneic stem cell transplant in people 28 days to 17 years [ID6410] | Technology appraisal guidance |
| Ruxolitinib for treating moderate atopic dermatitis [ID6602] | Technology appraisal guidance |
| Sabizabulin for treating COVID 19 [TSID11814] | Technology appraisal guidance |
| Sacituzumab govitecan for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment [ID6592] | Technology appraisal guidance |
| Sacituzumab govitecan for untreated PD-L1-negative triple-negative advanced breast cancer [ID6433] | Technology appraisal guidance |
| Sarizotan for the treatment of respiratory symptoms associated with Rett syndrome [ID1506] | Technology appraisal guidance |
| Sasanlimab with BCG for treating high-risk non-muscle-invasive bladder cancer with papillary tumours or carcinoma in situ untreated with BCG [ID6454] | Technology appraisal guidance |
| Savolitinib with durvalumab for treating MET-driven unresectable advanced papillary renal cell carcinoma [ID6520] | Technology appraisal guidance |
| Savolitinib with osimertinib for treating EGFR-mutated MET-overexpressed or amplified advanced non-small-cell lung cancer after osimertinib
[ID6494] | Technology appraisal guidance |
| Secukinumab for treating giant cell arteritis in people 50 years and over [TSID12163] | Technology appraisal guidance |
| Secukinumab for treating relapsed polymyalgia rheumatica [ID6599] | Technology appraisal guidance |
| Selinexor for treating unresectable dedifferentiated advanced liposarcoma [ID3825] | Technology appraisal guidance |
| Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with neurofibromatosis type 1 [ID6385] | Technology appraisal guidance |
| Semaglutide for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease
[TSID12250] | Technology appraisal guidance |
| Semaglutide for treating type 2 diabetes [ID1450] | Technology appraisal guidance |
| Setmelanotide for treating acquired hypothalamic obesity in people 4 years and older
[ID6542] | Technology appraisal guidance |
| Sevabertinib for untreated HER2-positive advanced non-small-cell lung cancer [ID6616] | Technology appraisal guidance |
| Sibeprenlimab for treating IgA nephropathy [ID6604] | Technology appraisal guidance |
| Somapacitan for treating growth failure associated with being small for gestational age, Noonan syndrome or idiopathic short height [ID6536] | Technology appraisal guidance |
| Somapacitan for treating growth failure caused by Turner syndrome in people 2 to 17 years [ID6621] | Technology appraisal guidance |
| Sotagliflozin for treating type 2 diabetes [ID1657] | Technology appraisal guidance |
| Sparsentan for treating focal segmental glomerulosclerosis in people 8 years and over [ID3955] | Technology appraisal guidance |
| STG320 for treating allergic rhinitis or rhinoconjunctivitis caused by house dust mites [ID1278] | Technology appraisal guidance |
| STS101 for treating acute migraine [TSID11782] | Technology appraisal guidance |
| Subcutaneous efgartigmod with recombinant human hyaluronidase PH20 for treating primary immune thrombocytopenia [TSID11977] | Technology appraisal guidance |
| Subcutaneous mosunetuzumab for treating relapsed or refractory follicular lymphoma after 2 or more treatments TSID 12081 | Technology appraisal guidance |
| Surovatamig for treating relapsed or refractory B-cell acute lymphoblastic leukaemia after 2 or more lines of treatment in people 12 years and over [ID6630] | Technology appraisal guidance |
| Surovatamig for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more lines of treatment
[ID6631] | Technology appraisal guidance |
| Talazoparib with enzalutamide for untreated hormone-sensitive metastatic prostate cancer with a homologous recombination repair mutation [ID6460] | Technology appraisal guidance |
| Talquetamab with daratumumab for treating relapsed or refractory multiple myeloma after 1 or more lines of treatment including a proteasome inhibitor and lenalidomide [ID6625] | Technology appraisal guidance |
| Talquetamab with pomalidomide or teclistamab for treating relapsed or refractory multiple myeloma after 1 or more treatments including an anti-CD38 antibody and lenalidomide [ID6629] | Technology appraisal guidance |
| Tarlatamamb for treating small-cell lung cancer that has progressed after platinum-based
chemotherapy [ID6617] | Technology appraisal guidance |
| Tasimelteon for treating sleep disturbance associated with Smith-Magenis syndrome [TSID12191] | Technology appraisal guidance |
| Teclistamab for treating relapsed or refractory multiple myeloma after 1 or more treatments including an anti-CD38 antibody and lenalidomide [ID6628] | Technology appraisal guidance |
| Tideglusib for treating congenital or childhood onset myotonic dystrophy [ID3915] | Technology appraisal guidance |
| Tildrakizumab for treating active psoriatic arthritis [TSID12218] | Technology appraisal guidance |
| Timrepigene emparvovec for treating choroideremia [ID3916] | Technology appraisal guidance |
| Tiragolumab in combination for untreated advanced non-squamous non-small-cell lung cancer [ID6443] | Technology appraisal guidance |
| Tiragolumab with atezolizumab for treating locally advanced unresectable stage 3 non-small-cell lung cancer after at least 2 cycles of platinum-based chemoradiation [ID6250] | Technology appraisal guidance |
| Tiragolumab–atezolizumab for PD-L1-positive recurrent or advanced non-small-cell lung cancer untreated with checkpoint inhibitors [TSID12064] | Technology appraisal guidance |
| Tiratricol for treating Allan–Herndon–Dudley syndrome [ID6217] | Technology appraisal guidance |
| Tirzepatide for treating type 2 diabetes in people 10 to 17 years
[ID6539] | Technology appraisal guidance |
| Tislelizumab for untreated unresectable hepatocellular carcinoma [TSID10683] | Technology appraisal guidance |
| Tislelizumab with chemoradiation for treating localised oesophageal squamous cell cancer [ID5077] | Technology appraisal guidance |
| Tislelizumab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6304] | Technology appraisal guidance |
| Tocilizumab for treating systemic sclerosis [ID1396] | Technology appraisal guidance |
| Trastuzumab deruxtecan for neoadjuvant treatment of HER2-positive high-risk early breast cancer [ID6620] | Technology appraisal guidance |
| Trastuzumab deruxtecan for previously treated unresectable or advanced HER2-positive solid tumours [ID6511] | Technology appraisal guidance |
| Trastuzumab deruxtecan for treating hormone receptor-positive HER2-low metastatic breast cancer after 2 or more endocrine treatments [ID6226] | Technology appraisal guidance |
| Trastuzumab deruxtecan for untreated HER2-mutated unresectable advanced non-small-cell lung cancer [ID6603] | Technology appraisal guidance |
| Trastuzumab deruxtecan with or without pertuzumab for untreated HER2-positive metastatic breast cancer [ID6548] | Technology appraisal guidance |
| Treosulfan with fludarabine for non-malignant disease before allogeneic stem cell transplant [ID1540] | Technology appraisal guidance |
| Treprostinil diethanolamine for treating pulmonary arterial hypertension [TSID11772] | Technology appraisal guidance |
| Troriluzole for spinocerebellar ataxia [ID6456] | Technology appraisal guidance |
| Tucatinib with trastuzumab and pertuzumab for maintenance treatment of HER2-positive unresectable advanced breast cancer after induction chemotherapy [ID6402] | Technology appraisal guidance |
| Tucatinib with trastuzumab emtansine for treating HER2-positive unresectable or advanced breast cancer after a taxane, trastuzumab or both together [TSID11781] | Technology appraisal guidance |
| Upadacitinib for treating moderate to severe hidradenitis suppurativa in people 12 years and over [TSID12234] | Technology appraisal guidance |
| UX111 for treating mucopolysaccharidosis type IIIA [ID6540] | Technology appraisal guidance |
| Valoctocogene roxaparvovec for treating severe haemophilia A [ID3806] | Technology appraisal guidance |
| Veligrotug for treating thyroid eye disease
[TSID12253] | Technology appraisal guidance |
| Venetoclax with azacitidine for treating acute myeloid leukaemia before and after an allogeneic stem cell transplant [ID6468] | Technology appraisal guidance |
| Venetoclax with ibrutinib for treating relapsed mantle cell lymphoma [ID3879] | Technology appraisal guidance |
| Venglustat for treating type 3 Gaucher disease in people aged 12 and over after at least 3 years of enzyme replacement therapy [ID6295] | Technology appraisal guidance |
| VER-01 for treating chronic low back pain [TSID12251] | Technology appraisal guidance |
| Vilobelimab for treating COVID 19 [TSID11815] | Technology appraisal guidance |
| Vosoritide for treating achondroplasia in children and young people under 18 years [ID3807] | Technology appraisal guidance |
| WP1048 for treating grass pollen allergy in people aged 18 to 60 [TSID10467] | Technology appraisal guidance |
| Xeomin (botulinum neurotoxin type A) for treating lower limb spasticity [TSID11902] | Technology appraisal guidance |
| Zamtocabtagene autoleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more therapies [TSID10765] | Technology appraisal guidance |
| Zamtocabtagene autoleucel for treating relapsed or refractory diffuse large B-cell lymphoma when high-dose chemotherapy and autologous stem cell transplant are unsuitable [TSID10477] | Technology appraisal guidance |
| Zanubrutinib with rituximab for untreated mantle cell lymphoma when a stem cell transplant is unsuitable [TSID12241] | Technology appraisal guidance |
| Zavegepant for treating acute migraine
[TSID11998] | Technology appraisal guidance |
| Zilugisertib for preventing new heterotopic ossification lesions caused by fibrodysplasia ossificans progressiva in people 12 years and over [TSID12252] | Technology appraisal guidance |
| Zimislecel for treating type 1 diabetes in people 12 years and over with impaired hypoglycaemic awareness and severe hypoglycaemia [ID6624] | Technology appraisal guidance |
| Zolbetuximab with nab-paclitaxel and gemcitabine for untreated claudin 18.2-positive metastatic pancreatic cancer [ID6444] | Technology appraisal guidance |
| Zolbetuximab with nab-paclitaxel and gemcitabine for untreated claudin 18.2-positive metastatic pancreatic cancer [TSID12040] | Technology appraisal guidance |
| Zongertinib for treating HER2-mutated unresectable or metastatic non-small-cell lung cancer [ID6573] | Technology appraisal guidance |